Evgeny Dmitrievich Fedorov

Evgeny Dmitrievich Fedorov

Auto-generated profile, based on publicly available information

Evgeny Dmitrievich Fedorov

N.I. Pirogov Russian National Research Medical University; City Clinical Hospital No. 31 named after Academician G.M. Savelyeva

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2021 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
VIVladimir Ivashkin
Vladimir Ivashkin
IMIgor V. Maev
Igor V. Maev
TLT. L. Lapina
T. L. Lapina
EFE. D. Fedorov
E. D. Fedorov
ASA. A. Sheptulin
A. A. Sheptulin
Vladislav Vladimirovich TsukanovVladislav Vladimirovich Tsukanov
Vladislav Vladimirovich Tsukanov
Aim.The clinical guidelines are intended to supplement specialty decision-making for improved aid quality in patients with gastritis and duodenitis though acknowledging the latest clinical evidence and principles of evidencebased medicine.Key points.Gastritis is an inflammatory disease of stomach mucosa, with a separate definition of acute and chronic gastritis. Chronic gastritis is a cohort of chronic diseases uniting a typical morphology of persistent inflammatory infiltration, impaired cellular renewal with emergent intestinal metaplasia, atrophy and epithelial dysplasia of gastric mucosa. Oesophagogastroduodenoscopy (OGDS) or high-resolution OGDS with magnified or non-magnified virtual chromoendoscopy, including targeted biopsy for atrophy and intestinal metaplasia grading and neoplasia detection, are recommended to verify gastritis and duodenitis, precancer states and/or gastric mucosal changes. All chronic gastritis patients positive for H. рylori should undergo eradication therapy as aetiological and subsidiary for gastric cancer prevention. Chronic gastritis patients with symptoms of dyspepsia (epigastric pain, burning and congestion, early satiety), also combined with functional dyspepsia, are recommended proton pump inhibitors, prokinetics, rebamipide and bismuth tripotassium dicitrate in symptomatic treatment. With focal restricted intestinal metaplasia, follow-up is not required in most cases, mainly when advanced atrophic gastritis is ruled out in high-quality endoscopy with biopsy. However, a familial history of gastric cancer, incomplete intestinal metaplasia and persistent H. pylori infection render endoscopy monitoring with chromoendoscopy and targeted biopsy desirable once in three years. Patients with advanced atrophic gastritis should have high-quality endoscopy every 3 years, and once in 1–2 years if complicated with a familial history of gastric cancer.Conclusion.The recommendations condense current knowledge on the aetiology and pathogenesis of gastritis and duodenitis, as well as laboratory and instrumental diagnostic techniques, main approaches to aetiological H. pylori eradication and treatment of dyspeptic states.

15 May 2022 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
VIVladimir Ivashkin
Vladimir Ivashkin
AKA. G. Kriger
A. G. Kriger
AOA. V. Okhlobystin
A. V. Okhlobystin
MAM. A. Anischenko
M. A. Anischenko
SKS. S. Kardasheva
S. S. Kardasheva
OSO. S. Shifrin
O. S. Shifrin
Aim:to present modern methods of diagnosis and treatment of chronic pancreatitis for gastroenterologists, general practitioners and physicians.Chronic pancreatitis (CP) is a long-term inflammatory disease of the pancreas, manifested by irreversible morphological changes in the parenchyma and pancreatic ducts, which cause pain and/or persistent impairment of function. Current concept on the etiology of CP is reflected by the TIGAR-O classification. The criteria for establishing the diagnosis of CP include typical attacks of abdominal pain and/or clinical and laboratory signs of exocrine, endocrine insufficiency with the mandatory detection of characteristic morphological changes (calcifications in the parenchyma and pancreatic ductal stones, dilatation of the main pancreatic duct and its branches). CT, MRCP, and pancreatobiliary endosonography are recommended as the methods of choice to verify the diagnosis of CP. Conservative treatment of patients with CP is provided for symptom relief and prevention of complications. Individual cases with severe non-interactable abdominal pain, as well as a complicated course of the disease (development of ductal hypertension due to main pancreatic duct stones or strictures, obstructive jaundice caused by compression of the common bile duct, symptomatic postnecrotic cysts, portal hypertension due to compression of the portal vein or thrombosis of the splenic vein, persistent duodenal obstruction, pseudoaneurysm of the celiac trunk basin and the superior mesenteric artery) serve as an indication for endoscopic or surgical treatment. The Guidelines set out modern approaches to the diagnosis, conservative, endoscopic and surgical treatment of CP, and the prevention of its complications.Conclusion.The implementation of clinical guidelines can contribute to the timely diagnosis and improve the quality of medical care for patients with chronic pancreatitis.

21 May 2024 in Russian Journal of Gastroenterology, Hepatology, Coloproctology
Verified
Journal Article
Open access
PDF file
VIVladimir Ivashkin
Vladimir Ivashkin
IMIgor V. Maev
Igor V. Maev
РTР. V. Tsarkov
Р. V. Tsarkov
МKМ. Р. Korolev
М. Р. Korolev
DADmitrii Nikolaevich Andreev
Dmitrii Nikolaevich Andreev
АSА. А. Sheptulin
А. А. Sheptulin
Aim. The guidelines set out the modern methods of diagnostics and treatment of peptic ulcer and are created for gastroenterologists, primary care physicians, general practitioners, surgeons, endoscopists.Key points. The clinical guidelines contain modern views on the etiology and pathogenesis of peptic ulcer, its clinical features, methods of laboratory and instrumental diagnostics, the main approaches to conservative and surgical treatment. They include the criteria for assessment of the quality of medical care, the algorithm of the doctor's actions, as well as information for the patient.Conclusion. Knowledge of modern methods of diagnostics and therapy of peptic ulcers will contribute to improving the results of its treatment.

1 January 2022 in Endoscopic Surgery
Verified
Journal Article
Closed access
MKM.P. Koroljov
M.P. Koroljov
MAM.V. Antipova
M.V. Antipova
EDE.A. Drobjazgin
E.A. Drobjazgin
AZA.A. Zaharenko
A.A. Zaharenko
AMA.V. Meshkov
A.V. Meshkov
ASA.A. Shhjogolev
A.A. Shhjogolev

15 February 2021 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
IKI. E. Khatkov
I. E. Khatkov
RAR. G. Avanesyan
R. G. Avanesyan
GAG. G. Akhaladze
G. G. Akhaladze
ABA. G. Beburishvili
A. G. Beburishvili
ABA. Yu. Bulanov
A. Yu. Bulanov
ЦВЦвиркун Виктор Викторович
Цвиркун Виктор Викторович
The research was performed at the Loginov Moscow Clinical Scientific Center. It is based on Russian obstructive jaundice (OJ) consensus results, considered at the 45th annual Central Research Institute of Gastroenterology Scientific session Oncological issues in the gastroenterologist practice (1 March 2019). The article objective is to note the diagnostic and conservative treatment current issues in patients with OJ. The increase in the number of patients with OJ of different etiology provides problem actuality. In a large number of cases, medical treatment is delayed due to inadequate diagnostic and management, while correct patients routing today can be provided regardless of medical institution level. In this article the examination steps and conservative treatment role in patients with biliary obstruction management are presented.

10 April 2025 in Russian Journal of Allergy
Verified
Journal Article
Open access
PDF file
VKValeria O. Kaibysheva
Valeria O. Kaibysheva
EFEvgeny Dmitrievich Fedorov
Evgeny Dmitrievich Fedorov
SSSergey G. Shapovalyants
Sergey G. Shapovalyants
КОКайбышева Валерия Олеговна
Кайбышева Валерия Олеговна
ШГШаповальянц Сергей Георгиевич
Шаповальянц Сергей Георгиевич
Eosinophilic esophagitis is a T2 disease characterized by eosinophilic infiltration of the esophageal mucosa, subepithelial and submucosal fibrosis, and progressive dysphagia. Early diagnosis and appropriate treatment of eosinophilic esophagitis can prevent the development of strictures and other complications. The treatment of eosinophilic esophagitis includes the use of elimination diets, pharmacological therapy, and endoscopic dilation or bougienage of the esophageal strictures. The most effective drugs for achieving clinical and histological remission in eosinophilic esophagitis are proton pump inhibitors, topical glucocorticosteroids, and biological agents represented by monoclonal antibodies. Over time, the advantages of systemic monoclonal antibody therapies (anti-interleukin 4/13) over proton pump inhibitors and topical glucocorticosteroids have become evident, particularly in terms of their impact on mucosal inflammation and on remodeling of the esophageal wall. Currently, the only approved anti-interleukin drug for eosinophilic esophagitis is dupilumab, which has demonstrated high efficacy and safety in clinical trials and is approved for use in children aged 1 year and older, as well as in adults. Endoscopic dilation or bougienage is performed in patients with eosinophilic esophagitis who have esophageal strictures and stenosis (with an esophageal diameter 13 mm) following a course of pharmacotherapy. To this day, numerous questions remain regarding maintenance therapy, its duration, and predictors of disease progression. With the emergence of new biologic therapies for eosinophilic esophagitis, their accessibility, long-term efficacy, and safety have become critically important considerations. The article systemizes existing data on the treatment strategies for patients with eosinophilic esophagitis.